RT Journal Article
SR Electronic
T1 Therapeutic effect of modified double-dose photodynamic therapy in circumscribed choroidal haemangioma
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 425
OP 429
DO 10.1136/bjophthalmol-2021-319832
VO 107
IS 3
A1 Hyeong Ju Byeon
A1 Ji Hwan Lee
A1 Junwon Lee
A1 Eun Young Choi
A1 Yong Joon Kim
A1 Sung Chul Lee
A1 Christopher Seungkyu Lee
YR 2023
UL http://bjo.bmj.com/content/107/3/425.abstract
AB Aims To retrospectively compare the therapeutic effect of modified double-dose photodynamic therapy (PDT) with standard-dose PDT in patients with circumscribed choroidal haemangioma (CCH).Methods Thirty-nine patients with CCH were categorised in two groups by PDT type. The standard-dose group (n=12) was treated with 6 mg/m2 verteporfin and a 689 nm laser for 83 s. The modified double-dose group (n=27) received one vial of verteporfin (15 mg), and the dose was calculated for each patient based on body surface area, then irradiance time was adjusted according to calculated verteporfin dose to achieve a ‘double’-dose effect. Treatment outcomes (foveal centre thickness, subretinal fluid, tumour thickness and diameter) were measured at baseline and 1 year post-treatment; subretinal fluid levels were also measured at 1, 3 and 6 months post-treatment.Results No differences in baseline characteristics were found between the two groups. The modified double-dose group showed a greater reduction in tumour thickness (45.3% vs 20.6%, p=0.013) and tumour volume (60.0% vs 30.0%, p=0.006) at 1 year post-treatment. Recurred or non-complete resolution patients in the standard-dose group tended to show much increased subretinal fluid than those in the modified double-dose group at 1-year post-treatment.Conclusion Modified double-dose PDT is an effective and safe protocol for symptomatic CCH management, greater tumour regression and potentially better resolution of subretinal fluid compared with standard PDT.Data are available upon reasonable request.